matejmo/E+ via Getty Images Patients treated with Invivyd's ( NASDAQ: IVVD ) Pemgarda (pemivibart) showed an 84% relative risk reduction in symptomatic COVID-19 compared to placebo in a phase 3 trial. In a group of all-comer immunocompetent individuals, 1.9% of treated individuals in a 180-day time period developed symptomatic COVID.
compared to 11.9% in the placebo group. Pemgarda currently has Emergency Use Authorization from the U.
S. FDA for COVID pre-exposure prophylaxis. Despite the results , shares are off 18% .
More on Invivyd Invivyd, Inc. (IVVD) Q2 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on Invivyd Historical earnings data for Invivyd Financial information for Invivyd.
